Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680677 · ClinicalTrials.gov registry record
Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
A clinical trial of MDS and Leukemia, Acute, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03680677 is a study of MDS and Leukemia, Acute that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03680677, a study of MDS and Leukemia, Acute, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Conditions Studied
Interventions
- PROCEDURE Bone Marrow or Peripheral Blood Graft (BMT)
- OTHER Cancer-directed Therapy or Best Supportive Care
- DIAGNOSTIC_TEST Frailty Assessment
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2026-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680677
The ClinicalTrials.gov registry entry for NCT03680677 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 22 other MDS trials with a reported enrollment target (79% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with MDS appearing as the primary indexed condition, and to 3 interventions - of which Bone Marrow or Peripheral Blood Graft (BMT) is the first listed.
NCT03680677 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03680677 about?
NCT03680677 is a clinical study titled "Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies". The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
What is the current status of trial NCT03680677?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2018-09-21. Estimated completion is 2026-11.
What conditions does trial NCT03680677 study?
This clinical trial studies the following conditions: MDS, Leukemia, Acute.
What interventions are being tested in trial NCT03680677?
The interventions under investigation include: Bone Marrow or Peripheral Blood Graft (BMT) (PROCEDURE), Cancer-directed Therapy or Best Supportive Care (OTHER), Frailty Assessment (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03680677?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680677 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.